| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Maravai LifeSciences Holdings, Inc.$6.25
-0.71 (-11.08%)
0Pipeline Score Tools & Services · Pre-Clinical
Market Cap
921.91 M
EPS
-0.71
P/E Ratio
-
Value Trade
23.81 M
SEC Financials
Q1 2026Dilution Risk
Revenue
65.84 M
R&D Expenses
3.89 M
Operating CF
8.66 M
Total Assets
713.22 M
Total Liabilities
344.13 M
Equity
211.56 M
-7.41 %
Week
5.57 %
1 Month
58.63 %
3 Month
102.27 %
6 Month
-88.28 %
5 Year
-86.23 %
All Time
Cash Data
Cash Position
165.92 M
Monthly Burn
-
Runway
-
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
1.47 M
52 Week Range
1.99 - 7.44
% held by Insiders
27.9 %
% held by Institutions
72.49 %
Enterprise Value
1.00 B
Total Shares
147.51 M
Short %
8.72 %
Float Shares
117.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Maravai LifeSciences Holdings, Inc.
143Total events
0Upcoming
20Tier-1 (high impact)
2020 – 2026Coverage
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Patent GrantedCleanCapIP / Competition
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 1%
Micro Cap (rank 915 of 923)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRVI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MRVI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MRVI▼ -11.1%today
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Maravai LifeSciences Holdings, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $51.4 million. The company experienced a net loss of $(21.6) million but raised its full-year 2026 Adjusted EBITDA guidance to between $33 million and $35 million. This reflects ongoing financial challenges despite positive revenue growth.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
Maravai LifeSciences, Inc. will announce its second quarter financial results on August 6, 2026. Following the announcement, a conference call and webcast will take place at 2:00 p.m. PT/5:00 p.m. ET. Participants can join the call via telephone using provided numbers.
Read more →MRVITriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
TriLink BioTechnologies has been awarded a new patent in China for its CleanCap capping technology, specifically covering methods for synthesizing RNA molecules. This patent includes the latest M6 analog and enhances TriLink's global intellectual property portfolio. The CleanCap technology is essential for various RNA applications, marking a significant advancement for the company.
Read more →MRVITriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
TriLink has opened a new GMP enzyme manufacturing facility in Jupiter, Florida, aimed at streamlining the sourcing of critical materials for RNA therapeutics. This facility offers a coordinated supply of key raw materials, enhancing efficiency from research to commercial production. The flagship product, GMP CleanScribe™ RNA Polymerase, significantly reduces double-stranded RNA formation, improving product quality.
Read more →MRVITriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
TriLink has announced the opening of a new GMP enzyme manufacturing facility. This facility is designed to provide integrated in vitro transcription (IVT) supply, facilitating the transition from research and development to commercial scale production. The move is expected to meet the increasing demand for enzyme production in the biopharma sector.
Read more →MRVIMaravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences has announced a refinancing of its credit agreement, extending the maturity date to 2032. This move aims to improve the company's financial flexibility and stability. The details of the refinancing are not disclosed in the announcement.
Read more →MRVIMaravai LifeSciences To Attend The Jefferies Global Healthcare Conference
Maravai LifeSciences is scheduled to attend the Jefferies Global Healthcare Conference. This event is significant for the company as it provides an opportunity to engage with investors and industry peers. Details regarding the specific presentations or discussions have not been disclosed.
Read more →MRVIMaravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance during this period. However, specific details regarding revenue, expenses, or future outlook are not included in the text provided.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026
Maravai LifeSciences, Inc. plans to announce its Q1 2026 financial results on May 7, 2026. Following the announcement, a conference call and webcast will be held at 2:00 p.m. PT. Participants can join by phone or via the company's website. Maravai specializes in life science reagents and services.
Read more →MRVI▲ +9.2%on this news
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences reported its financial results for Q4 and the full year 2025, highlighting a return to positive Adjusted EBITDA and exceeding revenue expectations. Despite a decrease in revenue and a net loss, the company is optimistic about operational improvements and revenue growth for 2026. The updated reporting segments reflect a strategic focus on its core business areas.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
Maravai LifeSciences, Inc. plans to announce its fourth quarter and full year 2025 financial results on February 25, 2026. The company will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET. Participants can join via telephone or through the company's website.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Organizational restructuring and operating cost reduction initiatives on track SAN DIEGO, Calif.
Maravai LifeSciences reported its financial results for the third quarter of 2025, showing a total revenue of $41.6 million, down 39.7% from the previous year. The company encountered a net loss of $(45.1) million, primarily due to reduced revenue in Nucleic Acid Production, which fell 52.9% year-over-year. Despite these challenges, Maravai maintains a positive outlook, aided by growth in its Biologics Safety Testing segment and upcoming projections for future revenue enhancement.
Read more →MRVIMARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders
Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences on behalf of long-term stockholders. This follows a class action complaint filed alleging that the company breached fiduciary duties. The complaint concerns inaccuracies in revenue recognition, with Maravai acknowledging a material weakness in internal controls. As a result of the negative news, Maravai's stock price saw a significant drop.
Read more →MRVI▼ -5.4%on this news
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. due to a class action complaint regarding potential breaches of fiduciary duties by its board. A revenue recognition error revealed prior to the company's fiscal 2024 earnings release led to a significant drop in share price. The complaint alleges that Maravai misled investors by failing to disclose material adverse facts about its operations. The investigation encourages long-term stockholders to reach out for information on their rights regarding these developments.
Read more →MRVI▲ +9%on this news
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences on behalf of long-term stockholders after a class action complaint was filed. The investigation follows Maravai's disclosure of a revenue recognition error and a material weakness in internal controls. Furthermore, the company's shares fell significantly after the announcement, indicating investor concern. The law firm encourages affected investors to reach out for legal discussion regarding their rights and potential claims.
Read more →MRVI▲ +30.6%on this news
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences reported a 31.7% decrease in revenue for Q2 2025, totaling $47.4 million. Despite a 5% growth in base business revenue, the company faces significant net losses and has withdrawn its revenue guidance for 2025 amid a leadership transition. The CEO announced restructuring initiatives aimed at achieving over $50 million in annual cost savings.
Read more →MRVI▼ -6.4%on this news
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
Maravai LifeSciences, Inc. will announce its Q2 2025 financial results on August 11, 2025. Following the announcement, a conference call will be held at 2:00 p.m. PT/5:00 p.m. ET. Participants can join via telephone or through a live webcast on the company's investor website.
Read more →MRVIMARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. on behalf of long-term stockholders after the company announced a delay in its fiscal 2024 earnings report due to an error in revenue recognition. This issue led to a 21.7% drop in share price on February 25, 2025. A class action complaint has been filed alleging that Maravai's executives made materially false statements regarding the company's financial situation. The investigation aims to determine whether the company's board breached their fiduciary duties.
Read more →MRVIMaravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
Maravai LifeSciences has appointed Rajesh Asarpota as the new Chief Financial Officer, effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role. Asarpota, with extensive experience in the life sciences sector, will lead various financial and strategic teams to drive growth and profitability for the company.
Read more →MRVIMaravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. after a class action complaint was filed concerning alleged breaches of fiduciary duties by the company's board. This follows the company's announcement that it will postpone its fiscal 2024 earnings release due to an error in revenue recognition and concerns over internal controls. The complaint also claims that Maravai made misleading statements about its financial health, contributing to a significant drop in its stock price. The investigation seeks to determine the extent of any wrongdoing by the company's directors.
Read more →MRVIMaravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
Maravai LifeSciences has appointed Bernd Brust as its new CEO, succeeding Trey Martin. Brust brings over 30 years of experience in the life sciences sector and is expected to drive innovation and financial performance. The company aims to expand its leadership in biologics and genomic medicine while maintaining a strong financial foundation. Maravai will reassess its financial outlook during the upcoming earnings call.
Read more →MRVICORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Maravai LifeSciences has released its 2024 Sustainability Report, showcasing its commitment to sustainable growth and innovation. The report details advancements in product innovation, governance, and renewable energy initiatives. CEO Trey Martin emphasizes the importance of sustainability in fostering innovation and business resilience. The report aligns with global sustainability frameworks and goals.
Read more →MRVIMaravai LifeSciences Releases 2024 Sustainability Report
Maravai LifeSciences has published its 2024 Sustainability Report, showcasing advancements in product innovation, governance, and sustainable growth. The report highlights the company's commitment to embedding sustainability in operations, aiming to enhance business resilience and stakeholder value. Key achievements include enhanced greenhouse gas accounting and the appointment of an independent Chairman.
Read more →MRVI▲ +7.1%on this news
MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. reported its first quarter 2025 financial results, revealing a revenue of $46.9 million, which is a 27.0% decrease compared to the same time last year. The company experienced a significant net loss of $(52.9) million, which includes a goodwill impairment of $12.4 million. CEO Trey Martin noted that despite the challenges, the base business is growing, and the revenue guidance for the full year remains unchanged at $185.0 million to $205.0 million. Maravai attributes some of the revenue decline to a lack of orders related to commercial phase vaccine programs, impacting their nucleic acid production segment severely.
Read more →MRVIMaravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens Berman
Maravai LifeSciences Holdings, Inc. reported disappointing Q4 earnings for 2024, with a loss per share of $0.06, wider than the expected $0.04. Revenue fell short at $56.6 million compared to the consensus forecast of $56.67 million. Additionally, a securities class action lawsuit has been launched against the company for alleged false statements regarding its financial reporting and goodwill accounting. Following these developments, analysts downgraded Maravai's stock, slashing the price target by 50% due to concerns over its financial outlook.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
Maravai LifeSciences plans to announce its first quarter 2025 financial results on May 12, 2025, following the market close. The company will host a conference call and webcast for investors on the same day at 2:00 p.m. PT/5:00 p.m. ET. As a provider of essential life science products and services, Maravai serves numerous biopharmaceutical and biotech clients, underscoring its role in the advancement of drug therapies and diagnostics.
Read more →MRVIMaravai LifeSciences Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 5, 2025 Deadline to file Lead Plaintiff Motion.
Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit filed by investors who purchased securities between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai misled investors regarding its internal financial controls and improperly recognized revenue during the fiscal year 2024. Following a delay in the release of its annual earnings report, the company saw its stock price drop significantly. Investors have until May 5, 2025, to file a lead plaintiff motion.
Read more →MRVI▲ +8.8%on this newsshared move
Maravai LifeSciences Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 5, 2025 to Discuss Your Rights – MRVI
Maravai LifeSciences Holdings, Inc. is being sued for alleged securities law violations related to misleading financial statements during a specified class period. The lawsuit claims that the company failed to disclose issues regarding internal controls over financial reporting, leading to inaccurate revenue recognition and overstated goodwill. Shareholders who acquired shares during the class period from August 7, 2024, to February 24, 2025, are being urged to participate in the class action, with a deadline to register by May 5, 2025. The Gross Law Firm is handling the case and offering to assist affected shareholders in their recoveries.
Read more →MRVIMaravai LifeSciences (MRVI) Earnings Call Raises Questions Amid Legal Allegations – Hagens Berman
Maravai LifeSciences Holdings (MRVI) has faced significant financial turmoil, as its shares dropped nearly 6% following the disclosure of material weaknesses in its financial reporting. These challenges were exacerbated by a securities class action lawsuit alleging the company misled investors regarding its internal controls and revenue recognition practices. During a recent earnings call, CFO Kevin Herde admitted to errors in revenue recognition and disclosed an $11.9 million goodwill impairment charge related to its Alphazyme acquisition. As the investigation by Hagens Berman unfolds, the company is under scrutiny for its financial transparency and internal controls.
Read more →MRVIMaravai LifeSciences Holdings, Inc. (MRVI) Admits to Incorrect Revenue Recognition, Ineffective Internal Controls; Class Action Pending – Hagens Berman
Maravai LifeSciences Holdings, Inc. (MRVI) has warned investors against relying on its previously filed financial statements due to improper revenue recognition, leading to a near 6% drop in share prices. The company is facing a class action lawsuit for allegedly making false and misleading statements related to its financial reporting. Additionally, Maravai disclosed that its internal controls over financial reporting are ineffective, prompting concerns over overstated revenues and goodwill. A significant downgrade from an analyst also negatively affected investor confidence.
Read more →MRVIMaravai LifeSciences Holdings, Inc. (MRVI) Investors: May 5, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit pertains to alleged misleading statements made by the company during the Class Period from August 7, 2024, to February 24, 2025. Key accusations include inadequate financial reporting controls and overstated goodwill. Investors have until May 5, 2025, to seek lead plaintiff status in the case.
Read more →MRVIMaravai LifeSciences Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before May 5, 2025 to Discuss Your Rights – MRVI
Maravai LifeSciences Holdings, Inc. is currently involved in a class action lawsuit for alleged securities law violations. The Gross Law Firm has notified shareholders that during the class period from August 7, 2024, to February 24, 2025, the company purportedly issued materially false and misleading statements about its financial reporting and goodwill. These allegations suggest inadequacies in internal controls and could potentially affect investor recovery. Shareholders have until May 5, 2025, to register for the case.
Read more →MRVI▼ -6.4%on this newsshared move
Maravai LifeSciences Holdings, Inc. Class Action: The Gross Law Firm Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit stemming from allegations of financial misreporting during the class period from August 7, 2024, to February 24, 2025. Shareholders who purchased shares during this period are encouraged to register for participation in the lawsuit. The allegations include a lack of adequate internal controls over financial reporting, leading to inaccurate revenue recognitions and overstated goodwill. The deadline to seek lead plaintiff status in the lawsuit is May 5, 2025.
Read more →MRVIMaravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Maravai LifeSciences Holdings, Inc. (MRVI) has been hit with a securities class action lawsuit after delaying its Q4 and FY 2024 earnings release due to issues with revenue recognition and internal controls. The lawsuit alleges that the company made false statements regarding its financial reporting, including an overstatement of its goodwill and revenue for Q2 2024. The company's stock fell by over 21% following the announcement, leading to an analyst downgrade from outperform to neutral. Investors who have suffered losses during the specified period are urged to submit their claims.
Read more →MRVIMaravai LifeSciences Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights – MRVI
Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit claims that the company engaged in securities fraud between August 2024 and February 2025, citing issues such as inadequate financial reporting controls and material misstatements regarding revenue recognition and goodwill. Investors affected by this alleged fraud are encouraged to participate in the lawsuit, with a deadline to request lead plaintiff status set for May 5, 2025. Levi & Korsinsky has a strong track record in securities litigation, with no cost required for class members to participate.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Schedules Conference Call for Thursday
Maravai LifeSciences Holdings, Inc. reported its financial results for the fourth quarter and full year of 2024, revealing a substantial net loss of $259.6 million for the year. Despite the challenging financial performance, the company completed strategic acquisitions aimed at enhancing its capabilities in nucleic acid technologies. Maravai also noted a significant decrease in quarterly revenue, driven largely by reduced demand for its products. Leadership changes and a solid cash position following loan prepayments signal efforts to navigate the downturn and focus on future growth.
Read more →MRVIMaravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results
Maravai LifeSciences Holdings, Inc. reported its financial results for Q4 and the full year of 2024, with a significant net loss of $(259.6) million for the year. Quarterly revenue declined by 23.7%, primarily due to reduced demand in nucleic acid production and biologics safety testing. The company also appointed R. Andrew Eckert as the independent Chairman of the Board and completed several strategic acquisitions. Maravai plans to provide financial guidance for 2025 during an upcoming conference call.
Read more →MRVIMaravai LifeSciences Holdings, Inc. Class Action: Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit filed by Levi & Korsinsky, LLP, concerning alleged securities fraud. The lawsuit pertains to events occurring between August 7, 2024, and February 24, 2025, and claims that the company made false statements regarding its financial reporting and internal controls. Investors have until May 5, 2025, to seek the appointment as lead plaintiff. The firm emphasizes that class members can seek compensation with no out-of-pocket costs.
Read more →MRVIMaravai LifeSciences Holdings, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against MRVI
Robbins LLP has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. for allegations of improper revenue recognition and lack of adequate internal controls over financial reporting. The lawsuit affects shareholders who purchased MRVI securities between August 7, 2024, and February 24, 2025. Following the disclosure of these issues, the company's stock experienced a significant drop of over 21%. Shareholders have until May 5, 2025, to file papers for participation in the class action.
Read more →MRVI▲ +10.9%on this newsshared move
Maravai LifeSciences Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRVI
Maravai LifeSciences Holdings, Inc. is currently facing a class action securities lawsuit for alleged violations of securities laws. The lawsuit targets investors who experienced losses from August 7, 2024, to February 24, 2025, due to misleading statements regarding the company's financial reporting and internal controls. Allegations include inaccurate revenue recognition and overstated goodwill. Investors have until May 5, 2025, to participate in the lawsuit. Legal representation is being offered with no out-of-pocket costs.
Read more →MRVIMARAVAI ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Maravai LifeSciences Holdings, Inc. and Encourages Investors to Contact the Firm
Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C. for allegedly making false statements and failing to disclose critical information about its financial condition. The lawsuit pertains to allegations that Maravai inaccurately recognized revenue and overstated its goodwill. The company's share price experienced a significant decline of 21.70% following the announcement of revenue recognition errors and the postponement of its fiscal 2024 earnings release. Investors who purchased Maravai securities within the defined class period are encouraged to take action and may seek to be appointed as lead plaintiffs.
Read more →MRVI▼ -6.2%on this news· ran to -17% by day 3shared move
Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Maravai LifeSciences Holdings, Inc. (MRVI) experienced a 21% drop in share price after announcing the delay of its Q4 and FY 2024 earnings release, citing additional time needed for its year-end financial close. The company admitted to overstating its Q2 2024 revenue by approximately $3.9 million due to incorrect accounting practices. Furthermore, Hagens Berman has initiated an investigation into potential accounting misconduct related to the company’s revenue recognition and internal controls. Analysts have reacted by downgrading their ratings on Maravai shares as concerns about the firm's financial integrity grow.
Read more →MRVI▲ +5.6%on this newsshared move
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Maravai Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. for potential violations of federal securities laws related to the postponement of its earnings release. The postponement is due to an ongoing assessment of a possible non-cash impairment charge linked to the acquisition of Alphazyme LLC, alongside errors in revenue reporting. Following this news, Maravai's stock price experienced a sharp decline of 21.7%, closing at $3.14 per share, prompting concerns among investors.
Read more →MRVI▼ -21.7%on this newsshared move
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
Maravai LifeSciences has postponed its earnings release and conference call originally set for February 25, 2025. The delay is due to the need for additional time to assess a potential goodwill impairment charge and to resolve a revenue recognition error. The company plans to file its annual report on Form 10-K by March 18, 2025, and expects its revenue for 2024 to remain within previously announced guidance.
Read more →MRVIMaravai LifeSciences Announces Preliminary Unaudited 2024 Revenue
Maravai LifeSciences Holdings, Inc. announced preliminary unaudited revenue results for 2024, expecting to report figures near the midpoint of the guidance range ($255 to $265 million). The company plans to release full financial results on February 25, 2025, following its year-end closure process. However, the preliminary results may change due to various risks including potential audit adjustments. Maravai plays a critical role in providing life science reagents and services essential for biopharmaceutical and vaccine development.
Read more →MRVI▼ -6%on this news
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors Carl Hull to Retire as Executive Chairman
Maravai LifeSciences has appointed R. Andrew Eckert as the new Chairman of the Board of Directors, succeeding Carl Hull, who will retire as Executive Chairman. Hull, the founder of the company, expressed gratitude for his experiences and confidence in Maravai's future prospects. Eckert is noted for his extensive background in healthcare leadership, which is expected to guide the company towards significant growth. The board unanimously supports this leadership change as a strategic move for the company's long-term success.
Read more →MRVIMaravai LifeSciences Announces November 2024 Investor Conference Schedule
Maravai LifeSciences, Inc. (NASDAQ: MRVI) announced its participation in two investor conferences scheduled for November 2024. Key executives, including the CFO and CEO, will engage with investors at the Stifel Healthcare Conference in New York and the Jefferies Healthcare Conference in London. Both events will feature fireside chats, which will be available via live webcast on the company's Investor Relations website. This participation underscores Maravai's commitment to transparency and engagement with the investor community.
Read more →MRVI▼ -35.3%on this newsshared move
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
Maravai LifeSciences has announced its plan to acquire the DNA and RNA business of Officinae Bio, enhancing its mRNA manufacturing capabilities. The acquisition aims to leverage Officinae Bio's AI-enabled methodologies to support innovative nucleic acid therapies. This strategic move is expected to provide significant benefits to customers in developing new therapies. The deal is subject to regulatory approvals and is anticipated to close in early 2025.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R D SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. reported its third quarter 2024 financial results, showing a revenue of $65.2 million but a net loss of $176.0 million, significantly impacted by a goodwill impairment. The company announced plans to acquire the DNA and RNA business of Officinae Bio, which is expected to enhance its capabilities in nucleic acid-based therapies. Despite the innovative product launches and a commitment to support its customers, Maravai faces challenges with declining revenues and heightened operational losses.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024
Maravai LifeSciences, Inc. is set to announce its third quarter 2024 financial and operating results on November 7, 2024. Following this announcement, the company will host a conference call and webcast for stakeholders. Maravai is known for its role in supporting drug therapies, diagnostics, and the development of vaccines.
Read more →MRVIMaravai LifeSciences Announces August and September 2024 Investor Conference Schedule
Maravai LifeSciences, Inc. announced its participation in several investor conferences scheduled for August and September 2024. CEO Trey Martin will discuss the genomic medicine supply chain at the UBS conference and participate in fireside chats at both the Wells Fargo and Morgan Stanley Healthcare Conferences. Live webcasts of these events will be available for broader audience engagement. Maravai is recognized for its essential contributions to drug therapies and diagnostics.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. announced financial results for the second quarter ending June 30, 2024, reporting a revenue increase of 6.5% compared to the previous year, reaching $73.4 million. Despite this growth, the company recorded a net loss of $14.5 million, with overall revenue for the year-to-date period declining by 7%. The report highlighted strategic partnerships and product innovations aimed at expanding the company's market presence. However, challenges such as lower demand trends and uncertainties surrounding future guidance were also noted.
Read more →MRVIMaravai LifeSciences Appoints Trey Martin to Board of Directors Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experien
Maravai LifeSciences has appointed CEO Trey Martin to its Board of Directors, effective July 31, 2024. His appointment reflects the company's commitment to innovation and leveraging his extensive industry experience. With over 25 years in life sciences, Martin aims to strengthen growth strategies and enhance decision-making alongside the Board. This move comes as Maravai seeks to bolster its position in drug therapies and diagnostics.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
Maravai LifeSciences, Inc. (NASDAQ: MRVI) will announce its second quarter 2024 financial results on August 7, 2024, after market close. A conference call and webcast are scheduled for the same day at 2:00 p.m. PT/5:00 p.m. ET. Maravai is known for providing essential life science products and services, particularly in nucleic acid synthesis and biologics safety testing. Investors and interested parties can participate by phone or through a live webcast available on the company's website.
Read more →MRVIMaravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
Maravai Lifesciences has released its 2023 Environmental, Social and Governance (ESG) report detailing progress across key areas, including product innovation and sustainable growth. The report emphasizes the company’s commitment to reducing greenhouse gas emissions and enhancing corporate governance. Notable achievements include the opening of the Analytical Sciences Center of Excellence and increased employee engagement in diversity and inclusion efforts. However, the report contains forward-looking statements about potential risks and uncertainties regarding operational performance and competitive pressures.
Read more →MRVI▲ +11.2%on this news
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
Maravai LifeSciences, Inc. (NASDAQ: MRVI) announced its investor conference schedule for May and June 2024. The company's CEO Trey Martin and CFO Kevin Herde will participate in fireside chats at the RBC Healthcare Conference in New York City on May 15 and the Goldman Sachs Healthcare Conference in Miami Beach on June 11. Live webcasts of these events will be available on their Investor Relations website, ensuring accessible updates for stakeholders. Maravai is recognized for providing essential life science products and services in the biopharmaceutical sector.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. reported its first quarter 2024 financial results, revealing a 19% decrease in revenues to $64.2 million compared to the previous year. The company also experienced a larger net loss of $(22.7) million, driven by lower demand for certain products related to COVID-19. In response, Maravai emphasized its continued focus on partnerships and product innovation, including new catalog launches and a recent facility opening in San Diego. Despite the financial setbacks, the firm reaffirmed its revenue guidance for the full year 2024, projecting between $265 million and $285 million.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
Maravai LifeSciences, Inc. (NASDAQ: MRVI) will announce its first quarter 2024 financial results on May 8, 2024, after the market closes. Accompanying the announcement, the company will host a conference call and webcast at 2:00 p.m. PT. Maravai specializes in providing life science reagents and services, supporting advancements in drug therapies and diagnostics.
Read more →MRVIMaravai LifeSciences Announces March 2024 Investor Conference Schedule
Maravai LifeSciences, Inc. (NASDAQ: MRVI) has announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum on March 19, 2024. CEO Trey Martin will conduct a fireside chat during the event, which will also be accessible via a live webcast. Maravai is recognized for supplying essential life science reagents and services that support advancements in drug therapies, diagnostics, and vaccines, pivotal in the industry.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. reported its financial results for Q4 and the full year 2023, revealing a significant net loss and alarming revenue declines. The company's total revenue for the fourth quarter was $74.1 million, representing a 64% decrease from the previous year. Key revenue segments, particularly Nucleic Acid Production, faced sharp declines attributed to reduced CleanCap demand following the pandemic. Despite these challenges, the company has set a revenue guidance range for 2024, indicating a continued commitment to innovation and market leadership.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
Maravai LifeSciences, Inc. is scheduled to announce its fourth quarter and full year 2023 financial results on February 22, 2024. Following the announcement, the company will host a conference call and webcast for investors to discuss these results. Maravai is recognized for its significant contributions to the life sciences sector, providing essential products that support drug therapy and vaccine development.
Read more →MRVIMaravai LifeSciences Announces November 2023 Investor Conference Schedule
Maravai LifeSciences has announced its participation in two investor conferences in November 2023. CEO Trey Martin and CFO Kevin Herde will engage in discussions at the Stifel Healthcare Conference in New York on November 14 and the Jefferies London Healthcare Conference on November 16. The company will provide live webcasts of these presentations on its Investor Relations website, ensuring that interested parties can access the events. Maravai is recognized for its contributions to drug therapies, diagnostics, and vaccine development.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market L
Maravai LifeSciences Holdings, Inc. reported its third quarter financial results, showing a significant decline in revenues due to decreased demand for its Nucleic Acid Production services. The company announced a strategic realignment initiative aimed at reducing operational costs, including a 15% workforce reduction. Despite these challenges, Maravai signed new partnerships to strengthen its product offerings and maintains an optimistic view on future growth potential in mRNA and biologics. Adjusted financial guidance for the full year suggests revenues will fall between $275 million and $285 million.
Read more →MRVIBehind the #MiracleMakers: TriLink’s Kieche O’Connell, PhD and her world of Catoms
Kieche O'Connell, PhD, a product manager at TriLink BioTechnologies, is revolutionizing chemistry education through her innovative 'Catoms' concept. This initiative uses cats to represent elements of the periodic table, making learning enjoyable for children. Kieche's diverse career journey highlights her adaptability and passion for science and education.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
Maravai LifeSciences, Inc. plans to reveal its third quarter 2023 financial and operational results on November 7, 2023. Following the announcement, the company will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET. Maravai is known for providing essential life science products and services, particularly in drug therapy and vaccine development. The call will be accessible via telephone and webcast for broader audience participation.
Read more →MRVIMaravai LifeSciences Hosts 2023 Investor R&D Day
Maravai LifeSciences hosted its 2023 Investor R&D Day, showcasing its robust foundation, innovative solutions, and long-term growth outlook. CEO Trey Martin emphasized the company's commitment to achieving high teens revenue growth and expanding EBITDA margins. The event highlighted Maravai's strengths in nucleic acid production and biologics safety testing, as well as a solid leadership team and strategic growth initiatives. Forward-looking statements shared during the event indicate potential risks tied to market demand, particularly for COVID-19 products.
Read more →MRVIMaravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100
Maravai LifeSciences announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, celebrating key leaders in the life sciences sector. Dr. Broderick, who joined Maravai in 2022, has a significant background in biotechnology, notably contributing to DNA vaccine development for COVID-19. Her role focuses on fostering innovation and strategic direction within the company, particularly in nucleic acid technology. The PharmaVoice 100 list has become a prestigious recognition program that highlights impactful figures in the life sciences industry.
Read more →MRVIMeet Maravai: Where extraordinary science delivers everyday miracles
Maravai LifeSciences is emerging as a key partner in the life sciences sector, providing essential services and materials to support the development of innovative vaccines, therapeutics, and diagnostics. With over 35 years of experience, Maravai offers a robust infrastructure and a commitment to quality that empowers biotech and pharma companies. Despite industry challenges, Maravai's innovative approach and extensive product portfolio position it as a vital ally in overcoming barriers to scientific advancement.
Read more →MRVIMaravai LifeSciences to Host 2023 Investor R&D Day
Maravai LifeSciences Holdings, Inc. will host its 2023 Investor R&D Day on September 28 in New York City. The event will feature presentations by CEO Trey Martin and other senior leaders, followed by a Q&A session. Participants can access a live webcast and expect a replay afterward. The company specializes in providing essential products for drug development, diagnostics, and vaccine production.
Read more →MRVIMaravai LifeSciences Announces August 2023 Investor Conference Schedule
Maravai LifeSciences, a leading provider of life science reagents, announced its participation in the UBS MedTech, Tools, and Genomics Summit on August 16, 2023. CEO Trey Martin and CFO Kevin Herde will conduct a fireside chat during the event. A live webcast of the presentation will be available for interested parties, with an archived version accessible after the event. Maravai continues to support innovations in drug therapies and diagnostics through its critical products and services.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif.
Maravai LifeSciences Holdings, Inc. reported a substantial financial downturn for Q2 2023, with revenues falling 72% to $68.9 million, largely due to reduced demand for COVID-19 related products. The company also reported a net loss of $11.9 million compared to profits in the prior year. Leadership changes are underway with Trey Martin stepping in as CEO and efforts to expand manufacturing capabilities in California and Florida. Maravai is adjusting its annual financial guidance to account for current market uncertainties.
Read more →MRVIMaravai LifeSciences Announces Completion of Planned CEO Leadership Transition William "Trey" Martin, III assumes the role of Maravai's CEO Carl Hull to continue to serve as Executive Chairman
Maravai LifeSciences has officially appointed William "Trey" Martin, III as the new Chief Executive Officer, following a planned succession process. Martin, who has over 25 years of experience in life sciences, previously led the Biologics Safety Testing segment. Carl Hull, the co-founder and previous interim CEO, will remain as Executive Chairman of the Board. Both leaders express confidence in the company's direction under Martin's leadership, emphasizing a commitment to the company's mission and growth.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023
Maravai LifeSciences Holdings, Inc. will announce its second quarter financial results after market close on August 7, 2023. Following the announcement, the company will hold a conference call and webcast at 2:00 p.m. PT. Maravai is recognized for supplying critical life science reagents and services, which are integral to drug development and diagnostics. The event signifies the company's ongoing communication with stakeholders and commitment to transparency in its operations.
Read more →MRVIMaravai LifeSciences Announces Appointment of New Director to the Board
Maravai LifeSciences appointed Dr. John DeFord as a new director to its Board, effective July 20, 2023. He fills the vacancy left by Robert Hance, who stepped down to take on the role of Chairman at the Medical Device Innovation Consortium. Dr. DeFord has a significant background in the medical technology sector and is expected to provide valuable insights to support Maravai's growth strategy. His appointment is part of Maravai's ongoing governance evaluation to ensure effective leadership as the company evolves.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif.
Maravai LifeSciences reported its first quarter 2023 financial results, revealing a significant revenue decline of 68% compared to the same period last year, attributed largely to lower demand for COVID-19 related products. The company introduced new technologies and product offerings, including advancements in mRNA Capping Technology and new ELISA kits. Despite a net loss of $1.3 million, they maintained a robust Adjusted EBITDA margin of 30.1%. Maravai has also expanded its manufacturing capacity in response to its evolving business needs and updated its financial guidance for the year ahead.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023
Maravai LifeSciences, a global provider of life science reagents and services, will announce its first quarter 2023 financial results after market close on May 8, 2023. Concurrently, the company will host a conference call at 2:00 p.m. PT/5:00 p.m. ET. This conference call and accompanying webcast will allow stakeholders to participate easily and access up-to-date information regarding the company's performance. Maravai is noted for its critical contributions to drug therapies, diagnostics, and vaccine development.
Read more →MRVIMaravai LifeSciences Releases 2022 Environmental, Social and Governance (ESG) Report
Maravai LifeSciences has released its 2022 Environmental, Social and Governance (ESG) report, detailing significant strides in transparency, environmental impact, and diversity initiatives. Key highlights include measuring greenhouse gas emissions, establishing new roles dedicated to sustainability, and demonstrating a commitment to diversity with a leadership team that is 50% women. The report aligns with leading sustainability frameworks and showcases Maravai's efforts to support stakeholders while promoting a culture of inclusion. The company continues to strengthen its governance practices and expand its operational capacity.
Read more →MRVIMaravai LifeSciences Announces March 2023 Investor Conference Schedule
Maravai LifeSciences, Inc. is scheduled to participate in key investor conferences in March 2023, featuring presentations from senior executives. The Barclays Global Healthcare Conference in Miami and the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum will host these discussions. Live webcasts will be available for both events to offer further engagement opportunities with investors. The company's ongoing commitment to transparency and investor communication is noteworthy.
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Base business revenues, excluding COVID-19 related CleanCap revenues, were up 67% in the fourth quarter and up 17% for the full year Announ
Maravai LifeSciences reported its fourth quarter and full year 2022 financial results, showing a 67% increase in base business revenues while total revenues declined by 10% year-over-year. Key highlights include the acquisition of Alphazyme, which enhances their enzyme manufacturing capacity, and an optimistic revenue guidance for 2023 projected between $420 million and $460 million. Despite strong overall growth, the company faced challenges with decreasing demand for COVID-related products and a drop in Nucleic Acid Production revenue. Net income for the fourth quarter was recorded at $87.4 million.
Read more →MRVIMaravai LifeSciences to Host Earnings Conference Call on Wednesday, February 22, 2023
Maravai LifeSciences, Inc. is scheduled to announce its fourth quarter and full year 2022 financial results on February 22, 2023. Following the announcement, the company will host a conference call and webcast at 2:00 p.m. PT. Maravai is recognized for providing essential products that support research and development in drug therapies and diagnostic solutions, serving various biotech and pharmaceutical companies.
Read more →MRVIMaravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William Trey Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will t
Maravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William Trey Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai s CEO in July 2023 Carl Hu
Read more →MRVIMaravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America
SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it ranked 270 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-
Read more →MRVI▼ -5.5%on this news
Maravai LifeSciences Announces November and December 2022 Investor Conference Schedule
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the months of November a
Read more →MRVI▼ -6.5%on this newsshared move
MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022 SAN DIEGO, Calif.
MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022 SAN DIEGO, Calif., - November 2, 2022 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life science reagents
Read more →MRVI▼ -13.2%on this news
Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit SAN DIEGO, Calif.
Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit SAN DIEGO, Calif., - October 19, 2022 - Executive Chairman and former CEO of Mara
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Wednesday, November 2, 2022
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2022 financial and operating results after the mark
Read more →MRVIMaravai LifeSciences Announces CEO Leadership Transition
William “Trey” Martin, III appointed to succeed Carl Hull as Chief Executive Officer Hull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents
Read more →MRVIMaravai LifeSciences Announces September 2022 Investor Conference Schedule
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of S
Read more →MRVIMARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS SAN DIEGO, Calif.
MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS SAN DIEGO, Calif., - August 4, 2022 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life science reagents and se
Read more →MRVI▲ +8.3%on this news
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2022 financial and operating results after the mar
Read more →MRVIMaravai LifeSciences Strengthens Executive Leadership Team to Support Long-Term Growth
SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that Peter Leddy, Ph.D. (“Pete”) has joined the Company as Executive Vice Preside
Read more →MRVIMaravai LifeSciences Announces May and June 2022 Investor Conference Schedule
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the months of May and Jun
Read more →MRVI▼ -6.4%on this news
MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance SAN DIEGO, Calif.
MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance SAN DIEGO, Calif., - May 5, 2022 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life science reag
Read more →MRVI▲ +6.4%on this news
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 5, 2022
SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2022 financial and operating results after the mar
Read more →MRVI▲ +5.9%on this news
Maravai LifeSciences Announces March 2022 Investor Conference Schedule
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March. On
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE SAN DIEGO, Calif.
MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE SAN DIEGO, Calif., - February 23, 2022 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life science reagents and services to r
Read more →MRVI▲ +8.1%on this news· ran to +21% by day 3
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene therapy market SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global pro
Read more →MRVIMaravai LifeSciences Announces Upcoming Investor Events
R&D Day - January 28, 2022 Q4 Earnings Conference Call - February 23, 2022 SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, will host a live vid
Read more →MRVIMaravai LifeSciences Announces Debt Repricing
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it had successfully completed the repricing of its existi
Read more →MRVIMaravai LifeSciences Announces Registration and Webcast Information for Upcoming R&D Day, to be Held on January 28, 2022
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced details for its first ever Investor R&D Day. The event will b
Read more →MRVIMaravai LifeSciences Added to the Nasdaq Biotechnology Index
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company has been added to the Nasdaq Biotechnology In
Read more →MRVIMaravai LifeSciences Announces Establishment of New Charitable Foundation
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it is establishing a new charitable foundation to promote caus
Read more →MRVIMARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022 SAN DIEGO, Calif.
MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022 SAN DIEGO, Calif., - November 10, 2021 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life scienc
Read more →MRVI▲ +6.3%on this news· ran to -18% by day 3
Maravai LifeSciences Announces November 2021 Investor Conference Schedule
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of Nov
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Wednesday, November 10, 2021
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2021 financial and operating results after the mark
Read more →MRVIMaravai LifeSciences Expands its Intellectual Property Portfolio with European Patent
SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the European Patent Office has issued a new patent, No. 3352584, to the comp
Read more →MRVI▼ -11.8%on this news
Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders
SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares
Read more →MRVIMaravai LifeSciences Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders
SAN DIEGO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the commencement of a public offering of its Class A
Read more →MRVIMaravai LifeSciences Announces September 2021 Investor Conference Schedule
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of Se
Read more →MRVI▼ -5.6%on this news
MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021
MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO - August 10, 2021 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ MRVI), a global provider of life science reagents and services to researchers and biotech innovat
Read more →MRVI▲ +6.1%on this news
Maravai LifeSciences To Host Earnings Conference Call on Tuesday, August 10, 2021
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2021 financial and operating results after the mar
Read more →MRVIMaravai LifeSciences Announces June 2021 Investor Conference Schedule
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of June
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021
MARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO - May 10, 2021 - Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ MRVI), a global provider of life science reagents and services to researchers and biotech innovators,
Read more →MRVIMaravai LifeSciences Announces Investor Conference Schedule for the Month of May 2021
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Monday, May 10, 2021
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2021 financial and operating results after the mar
Read more →MRVIMaravai LifeSciences Announces Closing of Secondary Offering of Class A Common Stock by Selling Stockholders and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of a public offering of 20,700,000 shares of Mara
Read more →MRVIMaravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of an upsized public offering of 18,000,000 share
Read more →MRVIMaravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from O
Read more →MRVIMARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE SAN DIEGO- Maravai LifeSciences Holdings, Inc. (Maravai or the Company)(NASDAQ MRVI), a global provider of life
MARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE SAN DIEGO-Maravai LifeSciences Holdings, Inc. (Maravai or the Company)(NASDAQ MRVI), a global provider of life science reagents and services to researchers and biotech in
Read more →MRVIMaravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing Services
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink Bi
Read more →MRVIMARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE SAN DIEGO- Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ MRVI), a global provider of life scie
MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE SAN DIEGO-Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ MRVI), a global provider of life science reagents and services to researchers and biotech innovat
Read more →MRVIMaravai LifeSciences Announces March 2021 Investor Conference Schedule
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences. On March 3, 2021, Car
Read more →MRVIMaravai LifeSciences Expands Its Intellectual Property Portfolio
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the United States Patent and Trademark Office has issued a new patent, Unite
Read more →MRVIMaravai LifeSciences To Host Earnings Conference Call on Tuesday, March 2, 2021
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2020 financial and operating results
Read more →MRVIMaravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Calif. - November 24, 2020 - Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services
Read more →MRVIMaravai LifeSciences Announces Pricing of an Upsized Initial Public Offering
SAN DIEGO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of its upsized initial public offering of
Read more →Competitive Position
How MRVI ranks across every disease it competes inCompetitive Position is a premium feature
See how MRVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial